<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>
International Journal of Nanomedicine2019Vol. Volume 14, pp. 7263–7279
Citations Over TimeTop 23% of 2019 papers
Abstract
RGDV-gemcitabine successively overcame the defects of gemcitabine and provided a practical strategy of nano-medicine.
Related Papers
- → Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer(2008)89 cited
- → Gemcitabine treatment enhances the activity of deoxycytidine kinase in periferial lymphocytes of patients with pancreatic cancer(2004)
- → Supplementary Figure 1 from The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase(2023)
- → Supplementary Figure 1 from The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase(2023)